Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted...

Area of Science:

• Oncology
• Pulmonology
• Radiation Oncology

Background:

• Oligometastatic non-small cell lung cancer (omNSCLC) is a distinct clinical subset with limited metastases.
• Advances in systemic therapies like immune checkpoint inhibitors (ICI) and targeted agents improve disease control.
• Local consolidative therapy, especially radiotherapy, shows promise in improving survival outcomes for omNSCLC.

Purpose of the Study:

• To review evolving treatment strategies for omNSCLC.
• To contextualize local therapies within systemic treatment frameworks (immunotherapy, targeted therapy).
• To clarify the role of local therapy in achieving long-term disease control for omNSCLC.

Main Methods:

• Review of current evidence on omNSCLC treatment strategies.
• Analysis of prospective clinical trials incorporating local therapy with systemic agents.
• Focus on radiotherapy as a primary local intervention modality.

Main Results:

• Combined systemic and local treatments can improve progression-free and overall survival in selected omNSCLC patients.
• Radiotherapy is a preferred local consolidation option, particularly when surgery is not feasible.
• Biomarker status, metastatic burden, and systemic therapy response guide treatment selection.

Conclusions:

• Local therapy, particularly radiotherapy, plays a crucial role in omNSCLC management when combined with systemic treatments.
• Optimizing the timing and modality of local interventions alongside immunotherapy and targeted therapy is key.
• Careful patient selection is essential for maximizing the benefits of multimodal treatment in omNSCLC.